TherapeuticsMD Q1 net loss narrows to $0.8M; strategic alternatives review ongoing

TherapeuticsMD, Inc.

2025-Q1 EPS reported -$0.06 revenue$313,000

Net loss from continuing operations of $0.8M ($0.07/share) vs. $2.3M ($0.24/share) in Q1 2023.
Gross license royalties of $1.2M under Mayne License Agreement; net royalties: $0.3M revenue and $0.3M other income.
Operating expenses down 52.8% to $1.5M from $3.1M, driven by transition to royalty-based model.
Cash and equivalents $4.3M at Mar 31, 2024; continues evaluating strategic alternatives including M&A or sale.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TherapeuticsMD, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.3 million, net income $(0.8) million, EPS $(0.07) per basic and diluted common share.

Period: the first quarter ended March 31, 2024
Revenue: $0.3 million
Net income: $(0.8) million
EPS: $(0.07) per basic and diluted common share
Result: reported results

Exact text from the filing

in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $0.3 million in revenue, net, and approximately $0.3 million in other income in the three months ended March 31, 2024 related to net license royalties. Total Operating Expenses from

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-041735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.